Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPR3 | P17342 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3863973 | 0.89 | ACHE (0.45) | ACHESLC6A4TDP1 | |
| SCHEMBL3870423 | 0.89 | NPSR1 (0.60) | NPSR1ACHESLC6A4KMT2AMEN1 | |
| SCHEMBL4169714 | 0.87 | NPSR1 (0.38) | NPSR1ACHESLC6A4KMT2AMEN1 | |
| SCHEMBL3874786 | 0.79 | ACHE (0.40) | ACHESLC6A4 | |
| SCHEMBL3864605 | 0.79 | NPSR1 (0.48) | NPSR1ACHESLC6A4KMT2AMEN1 | |
| SCHEMBL6712804 | 0.79 | NPSR1 (0.36) | NPSR1KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3863979 | 0.76 | ACHE (0.37) | ACHESLC6A4TDP1 | |
| SCHEMBL3867125 | 0.76 | ACHE (0.64) | ACHESLC6A4SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3866462 | 0.73 | RAB9A (0.47) | NPSR1ACHESLC6A4KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL3868777 | 0.72 | ACHE (0.67) | NPSR1ACHESLC6A4KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067981-A1 | Acetylcholinesterase inhibitor; Alzheimer's diseases, Hubtington disease, antidepressants | SANKYO COMPANY, LIMITED (JP) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067981-A1 | Acetylcholinesterase inhibitor; Alzheimer's diseases, Hubtington disease, antidepressants | ACHE, BACE1, CHRNA6 | NPSR1 864/4885ACHE 1/4885SLC6A4 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.